WB, IP, IF-IC
H M R
Endogenous
33
Rabbit IgG
#O60828
10084
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
| Immunofluorescence (Immunocytochemistry) | 1:100 - 1:400 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse, Rat
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human PQBP1 protein.
Background
Polyglutamine binding protein 1 (PQBP1) is an intrinsically disordered protein that is broadly expressed and evolutionarily conserved (1-3). PQBP1 has primarily been detected in the nucleus, though it has also been observed in the cytoplasm of mouse microglia (4,5). In the nucleus, PQBP1 is known to interact with mRNA splicing and RNA binding proteins, as well as the polyglutamine protein ataxin-1, and plays roles in both transcription and translation (4, 6-8). Mutations leading to loss of function of PQBP1 are associated with Golabi-Ito-Hall syndrome and Renpenning's syndrome, hallmarks of which include microcephaly and intellectual disability (9-11). Recently, PQBP1 has been reported to interact with tau protein, mediating activation of the cGAS-STING pathway in microglia (5). In the context of HIV-1 infection, PQBP1 also activates the cGAS-STING pathway by binding to reverse-transcribed HIV-1 DNA and cGAS, resulting in an innate immune response driven by IRF-3 (12).
- Takahashi, M. et al. (2009) Biochim Biophys Acta 1794, 936-43.
- Waragai, M. et al. (1999) Hum Mol Genet 8, 977-87.
- Okazawa, H. et al. (2001) Brain Res Bull 56, 273-80.
- Okazawa, H. et al. (2002) Neuron 34, 701-13.
- Jin, M. et al. (2021) Nat Commun 12, 6565.
- Mizuguchi, M. et al. (2014) Nat Commun 5, 3822.
- Llorian, M. et al. (2004) Biochem J 378, 229-38.
- Shen, Y. et al. (2021) Mol Cell 81, 1425-1438.e10.
- Stevenson, R.E. et al. (2005) Am J Med Genet A 134, 415-21.
- Lubs, H. et al. (2006) J Med Genet 43, e30.
- Kalscheuer, V.M. et al. (2003) Nat Genet 35, 313-5.
- Yoh, S.M. et al. (2015) Cell 161, 1293-1305.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation IF-IC: Immunofluorescence (Immunocytochemistry)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.